Coagulation factors after 3 days of acenocoumarol treatment and response to anticoagulant therapy according to CYP4F2 V433M and VKORC1 C1173T genotypes
| . | CYP4F2 V433M . | VKORC1 C1173T . | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| VV . | VM . | MM . | P . | β coefficient (P)* . | CC . | CT . | TT . | P . | β coefficient (P)* . | |
| n | 41 | 42 | 17 | NA | NA | 37 | 67 | 7 | NA | NA |
| FII† | 60 ± 12 | 66 ± 17 | 70 ± 11 | .005 | 0.263 (.013) | 66 ± 11 | 64 ± 15 | 61 ± 12 | .445 | 0.009 (.930) |
| FVII† | 12 (7-24) | 25 (13-44) | 38 (22-47) | .001‖ | 0.274 (.010) | 27 (14-38) | 20 (10-45) | 8.5 (6-14) | .044‖ | −0.013 (.904) |
| FIX† | 45 ± 21 | 59 ± 25 | 60 ± 15 | .016 | 0.307 (.003) | 52 ± 15 | 54 ± 26 | 32 ± 14 | .002 | −0.062 (.546) |
| FX† | 52 ± 14 | 57 ± 21 | 63 ± 15 | .082 | 0.203 (.055) | 43 ± 12 | 56 ± 19 | 58 ± 18 | .920 | 0.035 (.743) |
| INR‡ | 2.32 (1.72-3.20) | 1.84 (1.50-2.27) | 1.56 (1.34-2.04) | .015‖ | −0.277 (.007) | 1.74 (1.30-2.09) | 2.03 (1.69-2.79) | 2.96 (2.18-3.92) | .023‖ | 0.236 (.020) |
| Dose, mg/week§ | 15.3 ± 5.7 | 18.6 ± 6.0 | 18.8 ± 5.6 | .043 | 0.265 (.006) | 19.6 ± 5.9 | 16.0 ± 5.66 | 13.7 ± 4.7 | .018 | −0.321 (.001) |
| . | CYP4F2 V433M . | VKORC1 C1173T . | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| VV . | VM . | MM . | P . | β coefficient (P)* . | CC . | CT . | TT . | P . | β coefficient (P)* . | |
| n | 41 | 42 | 17 | NA | NA | 37 | 67 | 7 | NA | NA |
| FII† | 60 ± 12 | 66 ± 17 | 70 ± 11 | .005 | 0.263 (.013) | 66 ± 11 | 64 ± 15 | 61 ± 12 | .445 | 0.009 (.930) |
| FVII† | 12 (7-24) | 25 (13-44) | 38 (22-47) | .001‖ | 0.274 (.010) | 27 (14-38) | 20 (10-45) | 8.5 (6-14) | .044‖ | −0.013 (.904) |
| FIX† | 45 ± 21 | 59 ± 25 | 60 ± 15 | .016 | 0.307 (.003) | 52 ± 15 | 54 ± 26 | 32 ± 14 | .002 | −0.062 (.546) |
| FX† | 52 ± 14 | 57 ± 21 | 63 ± 15 | .082 | 0.203 (.055) | 43 ± 12 | 56 ± 19 | 58 ± 18 | .920 | 0.035 (.743) |
| INR‡ | 2.32 (1.72-3.20) | 1.84 (1.50-2.27) | 1.56 (1.34-2.04) | .015‖ | −0.277 (.007) | 1.74 (1.30-2.09) | 2.03 (1.69-2.79) | 2.96 (2.18-3.92) | .023‖ | 0.236 (.020) |
| Dose, mg/week§ | 15.3 ± 5.7 | 18.6 ± 6.0 | 18.8 ± 5.6 | .043 | 0.265 (.006) | 19.6 ± 5.9 | 16.0 ± 5.66 | 13.7 ± 4.7 | .018 | −0.321 (.001) |
Normally distributed values are expressed as mean ± SD, and not normally distributed values are expressed as median (interquartile range).
VV indicates homozygous V433 carriers; VM, heterozygous V433 M carriers; MM, homozygous M433 carriers; CC, homozygous C1173 carriers; CT, heterozygous C1173T carriers; TT, homozygous T1173 carriers; and NA, not applicable.
Multivariate linear regression analysis, including the effects of VKORC C1173T, CYP2C9, and CYP4F2 as predictors. Results from CYP2C9 genotypes were not significant and thus not shown.
Three days after starting therapy. All factors are IU/mL.
International normalized ratio (INR) 3 days after starting therapy as median (p25-p75).
After 3 months of therapy.
Kruskal-Wallis test. The other P values used analysis of variance test.